Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Corp.

MissionIRNewsBreaks – CYBIN Inc. Completes Reverse Takeover Transaction

CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an amalgamation agreement dated June 26, … Continue reading

Posted in Cybin Corp., MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Corp. Paves Path to Profitability with Health-Care Veteran at the Helm

Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/UTTdr). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than three decades of experience in … Continue reading

Posted in Cybin Corp. | Leave a comment

CYBIN Corp. Set to Benefit from Growing Research, Interest in Psychedelics

Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre for Psychedelic Science As an … Continue reading

Posted in Cybin Corp. | Leave a comment

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, … Continue reading

Posted in Cybin Corp. | Leave a comment

MissionIRNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space

Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in controlled settings and recent clinical … Continue reading

Posted in Cybin Corp. | Leave a comment

MissionIRNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of … Continue reading

Posted in Cybin Corp. | Leave a comment

MissionIRNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at … Continue reading

Posted in Cybin Corp. | Leave a comment

United Bid to Liberalize Use of Psilocybin Strengthens

Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model Cybin Corp. to capitalize … Continue reading

Posted in Cybin Corp. | Leave a comment

Cybin Corp. New CEO Set to Pave Path to Profitability, Grow IP Portfolio Organically

Cybin announces appointment of established pharma industry figure as new CEO Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space Announcement comes as Cybin sets out on path to profitability Cybin Corp., an innovative life science company developing … Continue reading

Posted in Cybin Corp. | Leave a comment

Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets

Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments As psilocybin continues to prove effective in treating mental health conditions, the company is … Continue reading

Posted in Cybin Corp. | Leave a comment